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A B S T R A C T   
Background: COVID-19 outbreak has adversely affected care of breast cancer patients world-wide. There is 
paucity of available data on cancer management in lower-middle income countries during this pandemic, we 
sought to determine the institutional approach towards management of breast cancer patients and the outcomes 
during COVID-19 pandemic at our institution. 
Materials and methods: Clinicopathological and treatment record of cancer patients who presented to the Breast 
Clinic from 15th March to 31st December 2020 was retrieved from the institutional database for this retrospective 
clinical observational study. 
Results: A total of 292 patients were qualified for the analysis in which 206 patients (70.5%) underwent breast 
cancer surgeries. Only 10 of them (4.9%) were identified to be COVID-19 virus positive on routine pre-operative 
RT-PCR test before elective surgeries. All were asymptomatic, received home-based care via telecommunication 
and were operated at a later date when test turned out negative. None of them developed any complications post- 
operatively. Another group of 86 patients (29.5%) were referred for Neoadjuvant/Systemic chemotherapy in 
which COVID-19 infection was detected in only 4 patients (4.6%) while receiving cycles. Two patients shown 
symptoms of cough and fever hence hospitalised but were not candidates for Intensive Care Unit admission while 
other two patient were asymptomatic and isolated at home. All patients recovered well and chemotherapy was 
commenced again after negative RT-PCR test. No mortality was observed. 
Conclusion: Despite of being a global crisis particularly for cancer patients we observed infectivity, complications 
and fatality much lower among breast cancer cases. Further research is needed in this regard including public 
and private sector hospitals for better understanding behavior of COVID-19 disease and achieve common goal to 
combat COVID-19 and cancer together.   
1. Introduction 
The fatal Coronavirus Disease 2019 (COVID-19) has emanated as a 
global pandemic unleashing a health and economic crises unprece-
dented in scope and magnitude. The infecting pathogen causing this 
disease was a beta coronavirus or severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) having its centre of origin in Wuhan, China 
where the first person contracting this infection was identified on 17th 
November 2019 [1,2]. Since then, it has gradually afflicted other 
countries of the world accounting for more than 97 million cases and 2 
million deaths by 24th January 2021 [3]. Pakistan is among the most 
affected victim of COVID-19 outbreak with limited resources to curb 
against severe expected outcomes, till to date 532,412 confirmed cases 
were reported [4]. This pandemic was an inciting panic for us because of 
many reasons as little is known about this disease, less understanding 
about appropriate treatment and unavailability of effective vaccine with 
evidence to affect immunocompromised cases including cancer patients 
more severely than others. 
Pakistan is a low middle income country with limited healthcare 
budget and limited resources. We have been facing serious consequences 
after being inflicted with COVID-19 outbreak as there is a lack of 
adequate testing facilities for COVID-19 country wide, insufficient 
supply of personal protective equipment for frontline responders and 
limited hospital capacity including ICU beds and ventilators. Moreover, 
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fear of COVID-19 positive detection on testing does not allow many 
including breast cancer patients to get their test done or to get admitted 
in hospital if symptomatic and bear their treatment expenses resulting in 
deterioration of their health and delay in receiving standard cancer 
treatment. 
The care of breast cancer patients has been adversely affected as a 
result of COVID-19 pandemic worldwide. There is a paucity of local data 
on breast cancer management during the attack of this contagion 
therefore our present study is designed to determine our institutional 
approach towards management of breast cancer patients and their out-
comes. This study will assist to curtail knowledge gaps and adds 
invaluable input to our breast cancer practices during COVID-19 crises. 
2. Material and methods 
After the attainment of Ethical exemption from the Ethics Review 
Committee of Aga Khan University Hospital (reference number: 2020- 
5418-14043) in Pakistan, a retrospective single-centre clinical obser-
vational study was conducted in breast surgery unit. The study was 
registered under the German Clinical Trials Register (DRKS) in accor-
dance with the declaration of Helsinki (Registration ID: DRKS00023807, 
https://www.drks.de/drks_web/navigate.do?navigationId=trial. 
HTML&TRIAL_ID=DRKS00023807) and was conducted according to 
the STROCSS statement guidelines 2019 [5]. 
As per the inclusion criteria only cancer patients who presented to 
Breast Clinic from 15th March to 31st December 2020 which either 
underwent surgery or referred for Neoadjuvant/Systemic treatment 
were included. Those patients with incomplete medical records or lost to 
follow-up were excluded from the analysis. Information on demographic 
data, clinicopathological and treatment characteristics was retrieved 
from the prospectively maintained Institutional Breast Cancer Data base. 
In late March formal guidelines were designed and approved by Multi-
disciplinary Breast cancer team to individualized treatment during 
COVID-19 crises (Table 1). Late in April formal COVID-19 testing was 
made mandatory 72 h preoperatively for all cases, elective cases were 
marked blue. The algorithm was designed to clearly outline plan in those 
cases who found positive on COVID testing, breast surgeries were 
categorized in Group B (Fig. 1 and 2). 
The data was collected on a self-designed proforma by the in-
vestigators. Information regarding age, grade, type, stage of breast 
cancer, immunohistochemical (IHC) status of oestrogen, progesterone 
and Her2 neu, co-morbid illness, neo-adjuvant chemo or hormonal 
therapy, type of surgery, pre-operative COVID-19 testing performed or 
not, testing result, whether surgery was deferred on the basis of result, 
post-operative hospital stay, development of any COVID-19 symptoms 
post-operatively during hospital stay or within one week after discharge 
or development of any surgical complications and survival status were 
collected for the analysis. Patients whose neo adjuvant treatments de-
ferred because of positive COVID-19 status were contacted by one of the 
authors to collect confirmed data about delay in treatment/repeat 
testing and number of repeat test with outcome in addition to reviewing 
electronic medical records as many patients had there testing done from 
outside AKUH. 
Data was analysed using statistical package for the social sciences 
(SPSS) (version 23.0). The categorical variables were represented by 
frequencies and percentages including procedures, COVID positivity, 
hormonal receptor status and quantitative variables like age were re-
ported as mean/median. 
3. Results 
Overall, the data analysis carried out revealed that in a study pop-
ulation of 292 patients, significant proportion of them were diagnosed of 
breast cancer at a median age of 48 years (range = 22–79 years) having 
diabetes mellitus (30.8%) being the most prevalent co-morbid medical 
ailment among them. More than half of the patients (90.1%) were 
identified with invasive ductal carcinoma of grade III (39.7%). Majority 
of patients (82.9%) presented with stage II/III disease and Luminal A 
was the most frequent molecular subtype seen in 35.9% of cases 
(Table 2). 
Following the hospital’s standard protocol, pre-operative COVID-19 
RT-PCR test was made mandatory within 72 h before elective surgeries 
(Fig. 1). Cases were categorized in three groups according to nature of 
disease, breast cancer surgeries were kept in group B (Fig. 2). Over all 
infectivity in elective surgeries at our institution from April–July 2020 
was 139/2456 (5.6%) and from August–December 2020 was 53/4631 
(1.1%). A total of 206 patients were subjected to Breast cancer surgeries 
and infectivity observed among these group from April–July was 07/66 
(10.6%) and from August–December was 03/140 (2.1%). All of these 
were asymptomatic hence quarantined at home. Besides this a tele-
communication network was established linking these COVID-19 posi-
tive patients with their primary consultant, infectious disease specialist 
and nurses to monitor their health and identify any worsening symptoms 
prompting admission in hospital. They were retested after 14 days as per 
designed guidelines and if test turned out negative surgery was per-
formed. There were 4 patients who were tested negative more than 4 
weeks after first positive test hence their procedures were performed 
after 5 weeks. The mean hospital stay was 24 h (18–27 h). None of the 
patients developed any signs and symptoms of COVID-19 disease or 
surgical complications post-operatively. All postoperative patients were 
asked to visit wound clinic once in a week, breast care nurse regularly 
monitored their wound through teleconsultations. 
A total of 74 patients received Neoadjuvant chemotherapy, 2 were 
kept on Neoadjuvant Hormonal Treatment while Stage IV disease was 
identified in 10 patients and referred subsequently for primary systemic 
Table 1 
Institutional approach to triaging of breast cancer surgery.  
Surgery (URGENT CARE) •Breast Abscess-consider aspiration otherwise 
I&D 
•Hematoma warranting evacuation 
•Ischemic Mastectomy flap warranting 
revision 
•Autologous reconstruction warranting 
revascularization/revision (No reconstruction 
to be performed during the Pandemic) 
•Progressive local disease on systemic therapy 
•Angiosarcoma 
•Malignant Phyllodes Tumours 
•T1NOM0 Triple negative tumours are high 
priority for surgery. May consider neoadjuvant 
chemotherapy for T1c. 
Surgery (Intervention May Be 
Altered or Delayed for 4–8 weeks) 
•Triple negative Invasive tumours, Post- 
Neoadjuvant chemotherapy are high priority 
for surgery, but surgery may be delayed by 4–8 
weeks until the health system is able to cope 
with the surgical cases 
•ER-/HER2+ Invasive tumours, Post- 
Neoadjuvant chemotherapy are high priority 
for surgery, but surgery may be delayed by 4–8 
weeks until the health system is able to cope 
with the surgical cases 
•Discordant core biopsies likely to be 
malignant on excision 
Surgery (Intervention May Be 
Delayed Until the Pandemic Is 
Over) 
•ER + tumours on Core biopsy, responsive to 
Neoadjuvant Endocrine therapy 
•ER- tumours on Core biopsy, responsive to 
Neoadjuvant Chemotherapy 
•DCIS (ER+/ER-), non-progressive 
•Margin re-excision 
•Sentinel Node for Invasive tumour identified 
on previous excision 
•High risk lesions (Atypia, Papilloma) 
•Benign-Borderline Fibro epithelial lesions 
(Fibro adenomas or Phyllodes) 
•Duct Excision for Nipple Discharge 
•Prophylactic surgery 
•Reconstruction  
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treatment. Out of which only 4 patients (4.6%) were tested positive for 
COVID-19 infection; two were symptomatic and both were treated in 
hospital as developed cough and low grade fever however none of them 
developed any serious complications or shifted to ICU. One was 75 years 
old lady with no comorbid while another was 53 years old having co-
morbid including diabetes, hypertension and recent cardiac bypass 
surgery, both recovered well. The treatment commenced after 4 weeks 
when symptoms resolved and were tested negative for COVID-19. Other 
two patients were completely asymptomatic and tested only because of 
positive exposure history hence kept in isolation for a week subse-
quently chemotherapy was commenced again. None of these individuals 
shown disease progression while kept off chemotherapy during this time 
period (Table 3). 
4. Discussion 
Pakistan reported first case of COVID-19 on 26th February 2020 who 
travelled from Iran, till that Pakistan has not designed any concrete 
policy to tackle this epidemic so as our institution [4]. However standard 
preventive measures were undertaken since early March. Late in March 
exponential increase in infectivity was a call to design robust policy in 
order to avoid perilous contagion spread in hospital, hence strategy was 
designed as per standard guidelines following worldwide [6]. Following 
that integrated multidisciplinary comprehensive breast cancer care 
guidelines were also designed incorporating recommendations from all 
the stakeholders. Mammographic screening, cancer surveillance ser-
vices, elective non-cancer surgeries and reconstructive surgeries had 
been temporarily suspended in the beginning. Non-urgent clinic ap-
pointments were deferred while videoconferencing and telehealth fa-
cilities were increasingly used amidst this unfurling health crises. 
Monitoring all patients and staff for the suspected COVID-19 infection 
and inquiring regarding travel history had been made mandatory before 
entering clinic or operation theatre. Specially designed negative pres-
sure air flow system were assigned to handle COVID-19 cases or emer-
gency cases whose COVID-19 status were not known which further 
controlled the situation within institution. Literature shown that 
Fig. 1. COVID testing algorithm for surgery patients.  
Table 2 
Demographic and clinicopathological data of breast cancer patients (N = 292).  
Patient characteristics Details N (%) 
Age at diagnosis <25 2 (0.7) 
25–45 98(33.6) 
46–65 170 (58.2) 
>65 22 (7.5) 
Comorbidities Diabetes 90 (30.8) 
Hypertension 115 (39.4) 
Ischemic Heart Disease 4 (1.4) 
None 83 (28.4) 
Histologic Type Invasive Ductal Carcinoma 263 (90.1) 
Invasive Lobular Carcinoma 8 (2.7) 
Metaplastic Carcinoma 11 (3.8) 
In-situ Ductal Carcinoma 5 (1.7) 
Papillary Carcinoma 2 (0.7) 
Mucinous Carcinoma 1 (0.3) 
Others 2 (0.7) 
Histologic Grade Grade 1 12 (4.1) 
Grade 2 164 (56.2) 
Grade 3 116 (39.7) 
Molecular Subtype Luminal A 105 (35.9) 
Luminal B 80(27.3) 
Triple Negative 68 (23.5) 
Her 2 enriched 39 (13.3) 
Tumor Stage (pathological) Stage 0 25 (8.5) 
Stage I 15 (5.2) 
Stage II 106 (36.3) 
Stage III 136 (46.6) 
Stage IV 10 (3.4)  
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guidelines have been efficaciously followed by every cancer care insti-
tute worldwide and literature search had shown promising results as a 
study conducted by Fregatti in Italy unravelled that if necessary pre-
ventive measures were fulfilled, neither patients nor health care workers 
tested positive for COVID-19 after breast surgery [7]. American College 
of Surgeons, ESMO and other cancer care organizations issued essential 
guidelines on the treatment strategies of breast cancer patients in order 
to deliver standardized quality care by mitigating exposure to COVID-19 
among patients and health care professionals without jeopardizing the 
health of them at the crucial time when health care resources are allo-
cated to participate more in ensuing COVID-19 outbreak response [8,9]. 
Breast cancer patients can easily become a victim of this virulent 
virus as compared to general population owing to their inherently 
fragile immune system as a consequence of their disease and anti- 
tumour therapies [10]. Our experience had shown that 10 out of 206 
(4.9%) breast cancer cases operated during the study time period found 
positive of COVID-19 virus, this rate was almost doubled in comparison 
to other elective surgeries apart from cancer 2.7% (192/7087) endorsing 
that cancer patients are at much higher risk than general population 
though all virus infected breast cancer patients were asymptomatic and 
none developed any sinister complication post-operatively. A large 
proportion of patients were also referred for Neoadjuvant treatment 
according to designed institutional guidelines including stage II- IV 
cases, 4 patients became positive during this treatment, and fortunately 
they recovered well without any complication. On contrary, figures re-
ported from multiple cancer institutes worldwide showed much higher 
infectivity rate and complications with increased mortality as study 
published from Wuhan reported incidence of infection among cancer 
cases (0.79%) found to be much higher than the overall incidence of 
COVID-19 cases over the same time period (0.37%) [10]. Likewise, 
another case series from China reported that cancer cases were associ-
ated with higher rate of complications including ICU admissions, inva-
sive ventilation or mortality (39% with cancer vs. 8% without cancer) 
[11]. Data by Vuagnat et al. from the Institut Curie hospitals, Paris 
revealed that out of 76 breast cancer patients having suspicion of 
COVID-19, 59 turned out to be positive [12]. 
Our data had shown that overall mortality rate in our institution 
among breast cancer cases affected with SARS-CoV-2 virus was 0%, 
again fatality rate from other institutions reported was up to 5.6% 
among cancer cases [13]. Onder et al. from Italy reviewed demographics 
of cases succumbed to COVID-19 and found 20.3% were cancer patients 
(72 cancer patients out of 355 deaths). They attributed different factors 
responsible for such high death rate among cancer cases including 
frequent hospital visits, immunocompromised state, and advanced age, 
co morbid or poor functional status [14]. 
Our results endorsed the fact that infectivity and mortality rate in 
Pakistan is comparatively much less than other nations of the world as a 
result of this contagion. The anecdotal evidence from India has also 
proven the fact that despite of high viral load and infectivity among 
community mortality rate is much lower. Several theories had been put 
forward to explain this odd response to COVID-19, this may be attrib-
uted because the virus responsible for infecting people here must had 
undergone mutation rendering it less virulent or might population have 
robust levels of immunity against it due to life time exposure to high 
microbial load like dengue, malaria, typhoid or universal BCG vacci-
nation all being a source to develop innate and adaptive immunity. The 
cross immunity or genetic diversity in immune responses, ACE 2 gene 
lays on the X-chromosome has additional advantage allowing females to 
be potentially heterozygous or environmental factors like high temper-
ature and high humidity in Karachi could be the reason for lower sus-
ceptibility to COVID-19 [15,16]. 
5. Limitations 
Understanding the fact that there are certain limitations of this study 
as being a single center experience having small sample size which 
might not be a true representative of the entire population plus the 
number of surgeries performed in the COVID-19 era decreased signifi-
cantly as compared to pre-COVID-19. The management guidelines 
Fig. 2. Plan for elective surgeries.  
Table 3 
Treatment Data and COVID-19 status of Breast Cancer Patients (N = 292).  
Patient characteristics Details N (%) 






Surgical Procedure (n = 206) Modified Radical Mastectomy 94 
(45.6) 





Surgery + Sentinel node biopsy 
66 
(32.1) 





Systemic Treatment (n = 86) Neo adjuvant Chemotherapy 74 
(86.1) 
Systemic Chemotherapy 10 
(11.6) 
Hormonal Treatment 2 (2.3) 
COVID 19 status in patients on 
Neoadjuvant/Systemic 
Chemotherapy. (n = 86) 
Positive 4 (4.6) 
Negative 82 
(95.4)  
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outlined in our study can be of great source of help to other institutions 
who are providing cancer care during the attack of this contagion in the 
presence of finite health care resources and workforce. More research is 
needed in this regard including other institutions from public and pri-
vate sector for better understanding behavior of COVID-19 disease and 
achieve common goal to tackle COVID-19 and cancer together. 
6. Conclusion 
Timely planning, multidisciplinary management and implementa-
tion of health policies kept infectivity and fatality rate among breast 
cancer cases and in general population much lower than one would 
expect in a low middle income country with high constraints to allocate 
health resources properly nationwide during COVID-19 pandemic. 
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